Logo

Genentech Will Use Dharmacon s RNAi Technology for Drug Discovery

Jan 21, 2005

NEW YORK, Jan. 21 (GenomeWeb News) - Genentech will use Dharmacon's RNAi technology in its drug-discovery research, Dharmacon said today.

 

Under the agreement, Dharmacon will supply Genentech with siRNA reagents, including its Human Druggable Genome library.

 

Dharmacon, a subsidiary of Fisher Scientific International, is located in Lafayette, Colo.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.